Uncertainty about the real-world effectiveness and value of a new product or a new indication can hinder market access, especially for products with no real-world data available or relatively small clinical trials. Value-based agreements (VBA) can help reassure payers in these circumstances and ensure that manufacturers earn an appropriate return in the event the product works as they expect it to.

Implementing VBAs requires that manufacturers answer a series of somewhat complex questions:

• What is the value of a treatment with uncertain effectiveness?
• How well do alternative VBA designs capture the value to the manufacturer?
• How will the VBA influence cash flow and revenues for the manufacturer?
• How will the VBA be adjudicated in practice?

EntityRisk has brought together a team of recognized experts uniquely positioned to answer these questions in any life sciences context.